MarketCapExport financials
Zosano Pharma Corporation (ZSAN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Zosano Pharma Corporation Balance Sheet 2021-2011 | ZSAN
Brief balance sheet overview of Zosano Pharma Corporation
This overview follows the five latest available annual observations between 2017 and 2021.
Assets reached $48.4 million, compared with $18 million at the beginning. Growth of +168.8% and CAGR near 28% show active expansion.
Liabilities grew more slowly than assets: +40.8% versus +168.8%. Expansion relied more on equity, improving funding quality.
Equity funds 68.1% of assets versus 39.2% initially. This creates a conservative balance sheet structure.
The balance sheet holds more cash than interest-bearing debt; net debt is -$6.4 million, indicating minimal leverage.
The cash share moved from 64.7% to 22.8%. A higher figure generally provides more room in an adverse scenario.
The balance sheet includes a negative accumulated result of -$362.1 million. It should be assessed alongside historical profits and capital distributions.
Overall assessment
Zosano Pharma Corporation has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Zosano Pharma Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.36 M | -33.1 M | 919 K | -2.34 M | -4.96 M | -2.46 M | 8.62 M | 12.1 M | 7.4 M | 4.05 M | - |
Long Term Debt |
3.08 M | 812 K | 6.1 M | 4.48 M | 6.69 M | 12.5 M | 15.3 M | 13.3 M | 9.71 M | 9.03 M | - |
Long Term Debt Current |
1.61 M | 1.38 M | 1.14 M | 2.33 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 4.49 M | 12 M | 5.78 M | 495 K | 6.6 M | 12 M | 13.4 M | 10.1 M | 9.63 M | - |
Total Current Liabilities |
11.1 M | 14.5 M | 16.2 M | 11.3 M | 10.5 M | 9.82 M | 6.88 M | 13.4 M | - | - | - |
Total Liabilities |
15.4 M | 24.5 M | 28.3 M | 17.1 M | 11 M | 16.4 M | 18.8 M | 26.7 M | 21.6 M | 13.6 M | - |
Deferred Revenue |
26 K | - | - | - | - | - | - | 170 K | 1.12 M | 3.38 M | - |
Retained Earnings |
-362 M | -332 M | -299 M | -261 M | -226 M | -197 M | -167 M | -138 M | -124 M | -119 M | - |
Total Assets |
48.4 M | 72 M | 37.7 M | 35.8 M | 18 M | 20.9 M | 45.3 M | 13.3 M | 22.1 M | 19.6 M | - |
Cash and Cash Equivalents |
11 M | 35.3 M | 6.32 M | 9.14 M | 11.7 M | 15 M | 6.65 M | 1.21 M | - | - | - |
Book Value |
33 M | 47.5 M | 9.39 M | 18.7 M | 7.05 M | 4.48 M | 26.5 M | -13.4 M | 477 K | 6.02 M | - |
Total Shareholders Equity |
33 M | 47.5 M | 9.39 M | 18.7 M | 7.05 M | 4.48 M | 26.5 M | -13.4 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Zosano Pharma Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 2.66 M | - | - | - | 204 K | 812 K | 1.42 M | 888 K | 10 K | - | 20 K | 25 K | 30 K | - | - | 3.6 M | - | 6.69 M | 8.18 M | 9.63 M | 11.2 M | 12.5 M | 14 M | 15.4 M | 15.3 M | 15.3 M | 15.2 M | 15.1 M | 15.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 12.4 M | 15.4 M | 16.8 M | 17.8 M | 22.6 M | 24.5 M | 25.2 M | 29.2 M | 31.4 M | 28.3 M | 26.3 M | 26.8 M | 25.9 M | 17.1 M | 10.4 M | 9.15 M | 11.4 M | 11 M | 11.6 M | 12.7 M | 14.7 M | 16.4 M | 18 M | 18.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 26.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 26 K | 47 K | 226 K | 47 K | - | - | - | - | - | - | - | - | - | - | 62 K | - | - | - | - | - | - | - | - | - | - | - | - | 68 K | 170 K | 170 K | 170 K | 170 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | -396 M | -362 M | -355 M | -346 M | -340 M | -332 M | -324 M | -315 M | -308 M | -299 M | -290 M | -280 M | -271 M | -261 M | -251 M | -243 M | -234 M | -226 M | -218 M | -211 M | -204 M | -197 M | -189 M | -182 M | -175 M | -167 M | -159 M | -151 M | -143 M | -138 M | -138 M | -138 M | -138 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | 26.4 M | 48.4 M | 55 M | 60.8 M | 65.7 M | 72 M | 80.5 M | 47.7 M | 55.3 M | 37.7 M | 36.7 M | 45.8 M | 35.5 M | 35.8 M | 38.9 M | 45.2 M | 10.4 M | 18 M | 25.9 M | 34.6 M | 43.2 M | 20.9 M | 30 M | 30.7 M | 37.5 M | 45.3 M | 53 M | 60.6 M | 66.4 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | 13.5 M | 11 M | 17.1 M | 22.1 M | 26.9 M | 35.3 M | 43.6 M | 10.5 M | 18.6 M | 6.32 M | 6.49 M | 14.3 M | 6.14 M | 9.14 M | 12 M | 16.2 M | 3.54 M | 11.7 M | 13.3 M | 21.2 M | 37.3 M | 15 M | 19.2 M | 10.1 M | 6.56 M | 6.65 M | 4.88 M | 8.06 M | 55.9 M | 1.21 M | 1.21 M | 1.21 M | 1.21 M | 5.91 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | 14.1 M | 33 M | 38.2 M | 43.1 M | 43.2 M | 47.5 M | 55.2 M | 18.5 M | 24 M | 9.39 M | 10.4 M | 19 M | 9.65 M | 18.7 M | 28.5 M | 36.1 M | -1.02 M | 7.05 M | 14.2 M | 22 M | 28.5 M | 4.48 M | 12 M | 12.6 M | 18.7 M | 26.5 M | 34.2 M | 41.8 M | 47.6 M | -13.4 M | 13.3 M | 13.3 M | 13.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | 14.1 M | 33 M | 38.2 M | 43.1 M | 43.2 M | 47.5 M | 55.2 M | 18.5 M | 24 M | 9.39 M | 10.4 M | 19 M | 9.65 M | 18.7 M | 28.5 M | 36.1 M | -1.02 M | 7.05 M | 14.2 M | 22 M | 28.5 M | 4.48 M | 12 M | 12.6 M | 18.7 M | 26.5 M | 33.9 M | 42.3 M | 49.5 M | -13.4 M | -13.4 M | -13.4 M | -13.4 M | 477 K | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Zosano Pharma Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Russia
Niderland
France
Israel
Australia
Danmark
